Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1216)	3/12/2004 4:27:16 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 1834

That's nice. When it comes to evaluating market size, likelihood of uptake and crunching the numbers LS really does a fine job. Or so I observe without any direct, personal experience.

To: Icebrg who wrote (1216)	4/8/2004 3:00:29 PM
From: Icebrg	Read Replies (1) \| Respond to of 1834

Neurocrine: sweet dreams for the twilight years Neurocrine Biosciences has completed its quartet of Phase III studies for indiplon. . . Indiplon now seems set to storm the insomnia market, boosted by Neurocrine's development and marketing agreement with pharmaceutical giant Pfizer. Datamonitor predicts that indiplon is on course for blockbuster status by 2010. Importantly, indiplon's impressive clinical development program eclipses that of Sepracor's Estorra (eszopliclone), the next insomnia drug expected to be launched later this year. As such, it is likely that Estorra will enjoy only a relatively short honeymoon period before indiplon takes market control. . . commentwire.com